Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Denali Therapeutics Inc (DNLI)

Denali Therapeutics Inc (DNLI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Denali Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants GlobeNewswire - Tue Dec 9, 11:14PM CST

SOUTH SAN FRANCISCO, Calif., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced the pricing of its underwritten public offering of 9,142,857 shares of its common...

DNLI : 17.98 (+3.51%)
Denali Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants GlobeNewswire - Tue Dec 9, 3:01PM CST

SOUTH SAN FRANCISCO, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced that it intends to offer and sell $200 million of shares of its common stock and,...

DNLI : 17.98 (+3.51%)
Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Funding Agreement GlobeNewswire - Thu Dec 4, 6:10AM CST

NEW YORK and SOUTH SAN FRANCISCO, Calif., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Denali Therapeutics, Inc. (Nasdaq: DNLI) today announced a $275 million synthetic royalty...

RPRX : 38.39 (-1.08%)
DNLI : 17.98 (+3.51%)
Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement GlobeNewswire - Thu Dec 4, 6:00AM CST

SOUTH SAN FRANCISCO, Calif. and NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) and Royalty Pharma plc (Nasdaq: RPRX) today announced a $275 million synthetic royalty...

RPRX : 38.39 (-1.08%)
DNLI : 17.98 (+3.51%)
Denali Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights GlobeNewswire - Thu Nov 6, 3:01PM CST

Tividenofusp alfa BLA review process for accelerated approval for MPS II continues with productive engagement with the FDA; commercial launch preparations on track DNL126 Phase 1/2 study enrollment completed,...

DNLI : 17.98 (+3.51%)
Denali Therapeutics Announces Board and Executive Leadership Updates GlobeNewswire - Thu Nov 6, 3:00PM CST

SOUTH SAN FRANCISCO, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced updates to its Board of Directors and executive leadership team. Tim Van Hauwermeiren...

DNLI : 17.98 (+3.51%)
Longevity Biotech Surges as $72.6B Market Forecast Sparks Investment Rush BayStreet.ca - Thu Oct 16, 8:23AM CDT

Issued on behalf of Avant Technologies Inc. VANCOUVER – Baystreet.ca News Commentary – The longevity and cell therapy sector has captured Wall Street's attention as market projections hit $72.6...

AUTL : 1.6100 (+1.26%)
AVAI : 0.3299 (+4.70%)
DNLI : 17.98 (+3.51%)
EDIT : 2.53 (-1.17%)
XNCR : 16.52 (-3.17%)
Oppenheimer Sticks to Its Buy Rating for Denali Therapeutics (DNLI) Tipranks - Wed Oct 15, 8:18AM CDT

In a report released today, Jay Olson from Oppenheimer maintained a Buy rating on Denali Therapeutics, with a price target of $35.00. The company’s shares closed yesterday at $14.98.Elevate Your Investing...

DNLI : 17.98 (+3.51%)
Wedbush Keeps Their Buy Rating on Denali Therapeutics (DNLI) Tipranks - Wed Oct 15, 7:46AM CDT

In a report released today, Laura Chico from Wedbush maintained a Buy rating on Denali Therapeutics, with a price target of $30.00. The company’s shares closed yesterday at $14.98.Elevate Your Investing...

DNLI : 17.98 (+3.51%)
Denali Therapeutics Faces FDA Review Extension Tipranks - Wed Oct 15, 7:30AM CDT

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Denali Therapeutics...

DNLI : 17.98 (+3.51%)

Barchart Exclusives

Inflation Data, AI Earnings and Other Can't Miss Items this Week Barchart - Sun Dec 14, 12:00PM CST
Markets enter a critical week still reeling from Friday's sharp selloff in technology and AI stocks following disappointing reactions to Oracle and Broadcom earnings that raised questions about AI infrastructure spending sustainability and return on massive capital investments. Here are 5 things to watch this week in the Market. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot